Prompt testosterone treatment improves mental health of transgender, gender-diverse people
2023-06-18
(Press-News.org) Receiving rapid access to testosterone therapy reduced feelings of gender dysphoria and led to a clinically significant reduction in depression as well as a 50% reduction in suicidality among transgender and gender diverse adults, according to research being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“This is the world-first randomized clinical trial supporting the significant benefits of testosterone in reducing gender dysphoria, depression and suicidality in trans individuals desiring commencement of testosterone,” said Brendan Nolan, M.B.B.S., F.R.A.C.P., a Ph.D. candidate at the University of Melbourne (Austin Health) in Melbourne, Australia.
Gender dysphoria occurs when a person feels distressed that their gender identity does not align with the sex assigned at birth. When an individual’s gender identity is not respected and the individual cannot access medical care, it can result in higher psychological problem scores and can raise the person’s risk of committing suicide or other acts of self-harm.
Nolan and colleagues sought to understand the impact of testosterone therapy compared with no treatment on gender dysphoria, depression, and suicidality in trans adults seeking masculinization.
The three-month open-label randomized controlled trial included 64 transgender adults who were able to start testosterone therapy immediately (intervention group) compared with those who were on a standard waiting list of three months prior to beginning testosterone. The purpose of this segmentation was to ensure no person would have to prolong waiting to begin treatment beyond standard care practices.
People who were able to begin treatment immediately showed decreased gender dysphoria and a clinically significant decrease in depression and suicidal ideation compared with study participants on the wait list.
Suicidal ideation resolved in 11 (52%) people with immediate testosterone therapy, compared with 1 (5%) given standard care, according to results from the Patient Health Questionnaire-9.
“Our findings illustrate the significant mental health benefits of early access to testosterone treatment and should provide an impetus for clinicians to ensure timely access to gender-affirming hormone therapy,” Nolan said.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-06-18
A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Among 82 transgender and gender-diverse adolescents treated at an academic pediatric endocrinology center from beginning of 2016 to end of 2018, only three chose to halt gender-affirming hormone therapy. None of them resumed identifying as their assigned sex at birth. One participant stopped hormonal therapy due to insurance ...
2023-06-17
Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.
“Hyperthyroidism or an overactive thyroid gland is common, affecting up to 3% of the population, and is associated with long-term adverse cardiac and metabolic consequences. The optimal treatment choice remains unclear,” said Kristien Boelaert, M.D., Ph.D., a professor of endocrinology from the University of Birmingham in the United Kingdom.
Boelaert and colleagues identified 55,318 patients ...
2023-06-17
Houston, TX – Candida auris, an emerging fungal pathogen resistant to many antimicrobial agents, continues to threaten U.S. public health. Researchers at bioMérieux Inc. conducted a retrospective analysis of blood cultures positive for C. auris and found an upsurge in detection of this pathogenic yeast between 2021 and 2023. The average detection rate of 0.014% before October 2022 (July 2020 to September 2022) rose to 0.057% after October 2022 (October 2022 to March 2023). They presented their findings at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.
The researchers investigated changes in C. auris infection rates geographically and over ...
2023-06-17
Houston, TX – New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial resistance. The findings are presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.
Antimicrobial resistance is a major threat to public health. Some bacteria are resistant to treatment because they produce the enzyme metallo-beta-lactamase, which make a certain class ...
2023-06-17
Houston, TX – Matching an infection with Candida auris, a pathogenic yeast, to an effective antifungal is a critical clinical decision. That decision relies on susceptibility testing, but commercially available antifungal tests perform poorly for many treatments, researchers at Indiana University and Indiana University Health have found. The investigators, who tested the accuracy of 4 available tests for use with C. auris, present their findings at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.
C. ...
2023-06-17
Transgender people who come to the emergency room for care tend to be sicker than cisgender people who are otherwise similar to them and are much more likely to be admitted to the hospital once they visit the ER, according to a study being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“Our findings suggest that decreasing discrimination against transgender people in society and in health care, and improving the outpatient care they are able to access in the community, may keep them healthier and help them avoid visits to the ER,” said lead researcher Daphna Stroumsa, ...
2023-06-17
CHICAGO—People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill.
Obesity is a significant public health issue affecting approximately 42% of people in the United States. Employees with overweight or obesity are more likely to develop weight-related comorbidities such as type 2 diabetes, hypertension, sleep apnea, cardiovascular ...
2023-06-17
CHICAGO—By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“The number of people with obesity is high and rising in the adult U.S. population. Obesity is a complex and expensive disease that has been implicated in many chronic conditions including high blood ...
2023-06-17
CHICAGO—Closed-loop insulin delivery systems improve glucose control in children with type 1 diabetes without causing adverse effects, according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
A closed-loop system consists of devices that use a continuous glucose monitor and insulin pump to automatically regulate blood sugar levels for people with diabetes. The system operates “closed-loop” because it continuously monitors and adjusts (starting and stopping) insulin delivery based on the person's ...
2023-06-17
A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel “robotic pill,” according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“We believe this study provides the first clinical evidence of safe and successful delivery of the osteoporosis drug teriparatide through an oral robotic pill,” said Arvinder Dhalla, Ph.D., who leads Clinical Development at Rani Therapeutics, the San Jose, Calif.-based company that developed the technology and funded the study. “Data from this study are very encouraging ...
LAST 30 PRESS RELEASES:
[Press-News.org] Prompt testosterone treatment improves mental health of transgender, gender-diverse people
